AU2021361067A1 - Compositions and methods for treating blood disorders - Google Patents

Compositions and methods for treating blood disorders Download PDF

Info

Publication number
AU2021361067A1
AU2021361067A1 AU2021361067A AU2021361067A AU2021361067A1 AU 2021361067 A1 AU2021361067 A1 AU 2021361067A1 AU 2021361067 A AU2021361067 A AU 2021361067A AU 2021361067 A AU2021361067 A AU 2021361067A AU 2021361067 A1 AU2021361067 A1 AU 2021361067A1
Authority
AU
Australia
Prior art keywords
antibody
clq
seq
amino acid
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021361067A
Other languages
English (en)
Other versions
AU2021361067A9 (en
Inventor
Sethu SANKARANARAYANAN
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of AU2021361067A1 publication Critical patent/AU2021361067A1/en
Publication of AU2021361067A9 publication Critical patent/AU2021361067A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021361067A 2020-10-16 2021-10-15 Compositions and methods for treating blood disorders Pending AU2021361067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093029P 2020-10-16 2020-10-16
US63/093,029 2020-10-16
PCT/US2021/055216 WO2022081997A1 (en) 2020-10-16 2021-10-15 Compositions and methods for treating blood disorders

Publications (2)

Publication Number Publication Date
AU2021361067A1 true AU2021361067A1 (en) 2023-06-01
AU2021361067A9 AU2021361067A9 (en) 2024-07-11

Family

ID=81208704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021361067A Pending AU2021361067A1 (en) 2020-10-16 2021-10-15 Compositions and methods for treating blood disorders

Country Status (8)

Country Link
US (1) US20230391858A1 (enExample)
EP (1) EP4228696A4 (enExample)
JP (1) JP2023545501A (enExample)
KR (1) KR20230087572A (enExample)
AU (1) AU2021361067A1 (enExample)
CA (1) CA3195798A1 (enExample)
MX (1) MX2023004429A (enExample)
WO (1) WO2022081997A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
KR20220083737A (ko) * 2019-10-17 2022-06-20 애넥슨, 인코포레이티드 혈액 장애를 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
AU2021361067A9 (en) 2024-07-11
CA3195798A1 (en) 2022-04-21
EP4228696A1 (en) 2023-08-23
KR20230087572A (ko) 2023-06-16
US20230391858A1 (en) 2023-12-07
JP2023545501A (ja) 2023-10-30
EP4228696A4 (en) 2025-03-26
MX2023004429A (es) 2023-07-11
WO2022081997A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
US20240109957A1 (en) Compositions and methods for treating blood disorders
US20240083989A1 (en) Compositions and methods for treating brain injury
EP3454901A1 (en) Compositions and methods for treating spinal muscular atrophy
WO2014169076A1 (en) Methods of treatment for neuromyelitis optica
WO2018017711A1 (en) Compositions and methods for treating frontotemporal dementia
US20230391858A1 (en) Compositions and methods for treating blood disorders
HK40077291A (en) Compositions and methods for treating blood disorders
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof